GlassScriptPhysician profile
Elizabeth Moore
NPI 1336717412
$738.14
in general payments reported to CMS, 2019-2025
14 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $53.33 · 2024: $117 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $177.22 | 2022-2025 | General - Pain Management |
| Globus Medical, INC. | $169.61 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $56.62 | 2025 | Belbuca, Xtampza |
| Depuy Synthes Sales INC. | $51.78 | 2022-2024 | Orthovisc, Monovisc |
| Vertex Pharmaceuticals Incorporated | $51.44 | 2025 | |
| Janssen Pharmaceuticals, INC | $38.86 | 2025 | Spravato |
| Kerecis Limited | $37.87 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Scilex Pharmaceuticals INC. | $37.64 | 2024-2025 | |
| Valinor Pharma, LLC | $22.81 | 2025 | Movantik |
| Biotronik Nro, INC. | $22.74 | 2024 | Prospera |
| Merz Pharmaceuticals, LLC | $21.10 | 2025 | Xeomin |
| Orthofix Medical, INC. | $19.82 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.60 | 2024 | Dysport |
| Bioventus LLC | $15.03 | 2025 | Xcell |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.